English
简体中文
Total: £ 56.28
Published Date: 2026-03-06 | Pages: 160 | Tables: 149 | Medical Care
The global Lipid Nanoparticle CDMO market was valued at US$ 742 million in 2025 and is anticipated to reach US$ 1140 million by 2032, at a CAGR of 6.3% from 2026 to 2032.
Lipid Nanoparticle CDMO refers to a specialized contract research and manufacturing service dedicated to supporting biopharmaceutical companies, biotech startups, and research institutions in the full lifecycle development and production of lipid nanoparticles— the gold-standard delivery vehicles for nucleic acid therapeutics including mRNA vaccines, siRNA gene silencing therapies, and CRISPR-based gene editing platforms.
The Lipid Nanoparticle CDMO industry is trending toward end-to-end integrated R&D-to-commercial services, automated continuous manufacturing, novel ionizable lipid development, and digital quality control; key opportunities stem from surging mRNA/siRNA/gene therapy pipelines, growing biotech outsourcing demand, and expansion into oncology and rare disease treatments, while main challenges include strict cGMP regulations, limited high-purity lipid supply, talent shortages, high capacity investment costs, and IP constraints for proprietary lipid formulations.
This report delivers a comprehensive overview of the global Lipid Nanoparticle CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lipid Nanoparticle CDMO. The Lipid Nanoparticle CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Lipid Nanoparticle CDMO market comprehensively. Regional market sizes by Type, by Application, by Service Scope & Project Stage, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Lipid Nanoparticle CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
GenScript
Creative Biolabs
Merck
Cytiva
WuXi STA
Carcell
Nippon Fine Chemical
Detai Biotechnology
MicroNano Biologics
Precigenome
Evonik
Lipoid
Helix Biotech
FUJIFILM Holdings
Ascendia Pharmaceuticals
Catalent
Polymun Scientific
Patheon
Biomay
Pace Analytical
CordenPharma
Vernal Biosciences
Lonza
Segment by Type
Formulation Development
cGMP Manufacturing
Others
Segment by Service Scope & Project Stage
Preclinical Development CDMO
Clinical Trial CDMO
Commercial Manufacturing CDMO
Segment by Manufacturing Technology
Batch Processing CDMO
Continuous Flow CDMO
Aseptic Fill-Finish Integrated CDMO
Segment by Application
Gene Therapy
Vaccine Development
Cancer Treatment
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Service Scope & Project Stage, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Lipid Nanoparticle CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lipid Nanoparticle CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Formulation Development
1.2.3 cGMP Manufacturing
1.2.4 Others
1.3 Market by Service Scope & Project Stage
1.3.1 Global Lipid Nanoparticle CDMO Market Size Growth Rate by Service Scope & Project Stage: 2021 vs 2025 vs 2032
1.3.2 Preclinical Development CDMO
1.3.3 Clinical Trial CDMO
1.3.4 Commercial Manufacturing CDMO
1.4 Market by Manufacturing Technology
1.4.1 Global Lipid Nanoparticle CDMO Market Size Growth Rate by Manufacturing Technology: 2021 vs 2025 vs 2032
1.4.2 Batch Processing CDMO
1.4.3 Continuous Flow CDMO
1.4.4 Aseptic Fill-Finish Integrated CDMO
1.5 Market by Application
1.5.1 Global Lipid Nanoparticle CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Gene Therapy
1.5.3 Vaccine Development
1.5.4 Cancer Treatment
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Lipid Nanoparticle CDMO Market Perspective (2021–2032)
2.2 Global Lipid Nanoparticle CDMO Growth Trends by Region
2.2.1 Global Lipid Nanoparticle CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Lipid Nanoparticle CDMO Historic Market Size by Region (2021–2026)
2.2.3 Lipid Nanoparticle CDMO Forecasted Market Size by Region (2027–2032)
2.3 Lipid Nanoparticle CDMO Market Dynamics
2.3.1 Lipid Nanoparticle CDMO Industry Trends
2.3.2 Lipid Nanoparticle CDMO Market Drivers
2.3.3 Lipid Nanoparticle CDMO Market Challenges
2.3.4 Lipid Nanoparticle CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lipid Nanoparticle CDMO Players by Revenue
3.1.1 Global Top Lipid Nanoparticle CDMO Players by Revenue (2021–2026)
3.1.2 Global Lipid Nanoparticle CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Lipid Nanoparticle CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Lipid Nanoparticle CDMO Revenue
3.4 Global Lipid Nanoparticle CDMO Market Concentration Ratio
3.4.1 Global Lipid Nanoparticle CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lipid Nanoparticle CDMO Revenue in 2025
3.5 Global Key Players of Lipid Nanoparticle CDMO Head Offices and Areas Served
3.6 Global Key Players of Lipid Nanoparticle CDMO, Products and Applications
3.7 Global Key Players of Lipid Nanoparticle CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Lipid Nanoparticle CDMO Breakdown Data by Type
4.1 Global Lipid Nanoparticle CDMO Historic Market Size by Type (2021–2026)
4.2 Global Lipid Nanoparticle CDMO Forecasted Market Size by Type (2027–2032)
5 Lipid Nanoparticle CDMO Breakdown Data by Application
5.1 Global Lipid Nanoparticle CDMO Historic Market Size by Application (2021–2026)
5.2 Global Lipid Nanoparticle CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Lipid Nanoparticle CDMO Market Size (2021–2032)
6.2 North America Lipid Nanoparticle CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Lipid Nanoparticle CDMO Market Size by Country (2021–2026)
6.4 North America Lipid Nanoparticle CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lipid Nanoparticle CDMO Market Size (2021–2032)
7.2 Europe Lipid Nanoparticle CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Lipid Nanoparticle CDMO Market Size by Country (2021–2026)
7.4 Europe Lipid Nanoparticle CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Lipid Nanoparticle CDMO Market Size (2021–2032)
8.2 Asia-Pacific Lipid Nanoparticle CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Lipid Nanoparticle CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Lipid Nanoparticle CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Lipid Nanoparticle CDMO Market Size (2021–2032)
9.2 Latin America Lipid Nanoparticle CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Lipid Nanoparticle CDMO Market Size by Country (2021–2026)
9.4 Latin America Lipid Nanoparticle CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lipid Nanoparticle CDMO Market Size (2021–2032)
10.2 Middle East & Africa Lipid Nanoparticle CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Lipid Nanoparticle CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Lipid Nanoparticle CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GenScript
11.1.1 GenScript Company Details
11.1.2 GenScript Business Overview
11.1.3 GenScript Lipid Nanoparticle CDMO Introduction
11.1.4 GenScript Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.1.5 GenScript Recent Development
11.2 Creative Biolabs
11.2.1 Creative Biolabs Company Details
11.2.2 Creative Biolabs Business Overview
11.2.3 Creative Biolabs Lipid Nanoparticle CDMO Introduction
11.2.4 Creative Biolabs Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.2.5 Creative Biolabs Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Lipid Nanoparticle CDMO Introduction
11.3.4 Merck Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.3.5 Merck Recent Development
11.4 Cytiva
11.4.1 Cytiva Company Details
11.4.2 Cytiva Business Overview
11.4.3 Cytiva Lipid Nanoparticle CDMO Introduction
11.4.4 Cytiva Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.4.5 Cytiva Recent Development
11.5 WuXi STA
11.5.1 WuXi STA Company Details
11.5.2 WuXi STA Business Overview
11.5.3 WuXi STA Lipid Nanoparticle CDMO Introduction
11.5.4 WuXi STA Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.5.5 WuXi STA Recent Development
11.6 Carcell
11.6.1 Carcell Company Details
11.6.2 Carcell Business Overview
11.6.3 Carcell Lipid Nanoparticle CDMO Introduction
11.6.4 Carcell Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.6.5 Carcell Recent Development
11.7 Nippon Fine Chemical
11.7.1 Nippon Fine Chemical Company Details
11.7.2 Nippon Fine Chemical Business Overview
11.7.3 Nippon Fine Chemical Lipid Nanoparticle CDMO Introduction
11.7.4 Nippon Fine Chemical Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.7.5 Nippon Fine Chemical Recent Development
11.8 Detai Biotechnology
11.8.1 Detai Biotechnology Company Details
11.8.2 Detai Biotechnology Business Overview
11.8.3 Detai Biotechnology Lipid Nanoparticle CDMO Introduction
11.8.4 Detai Biotechnology Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.8.5 Detai Biotechnology Recent Development
11.9 MicroNano Biologics
11.9.1 MicroNano Biologics Company Details
11.9.2 MicroNano Biologics Business Overview
11.9.3 MicroNano Biologics Lipid Nanoparticle CDMO Introduction
11.9.4 MicroNano Biologics Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.9.5 MicroNano Biologics Recent Development
11.10 Precigenome
11.10.1 Precigenome Company Details
11.10.2 Precigenome Business Overview
11.10.3 Precigenome Lipid Nanoparticle CDMO Introduction
11.10.4 Precigenome Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.10.5 Precigenome Recent Development
11.11 Evonik
11.11.1 Evonik Company Details
11.11.2 Evonik Business Overview
11.11.3 Evonik Lipid Nanoparticle CDMO Introduction
11.11.4 Evonik Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.11.5 Evonik Recent Development
11.12 Lipoid
11.12.1 Lipoid Company Details
11.12.2 Lipoid Business Overview
11.12.3 Lipoid Lipid Nanoparticle CDMO Introduction
11.12.4 Lipoid Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.12.5 Lipoid Recent Development
11.13 Helix Biotech
11.13.1 Helix Biotech Company Details
11.13.2 Helix Biotech Business Overview
11.13.3 Helix Biotech Lipid Nanoparticle CDMO Introduction
11.13.4 Helix Biotech Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.13.5 Helix Biotech Recent Development
11.14 FUJIFILM Holdings
11.14.1 FUJIFILM Holdings Company Details
11.14.2 FUJIFILM Holdings Business Overview
11.14.3 FUJIFILM Holdings Lipid Nanoparticle CDMO Introduction
11.14.4 FUJIFILM Holdings Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.14.5 FUJIFILM Holdings Recent Development
11.15 Ascendia Pharmaceuticals
11.15.1 Ascendia Pharmaceuticals Company Details
11.15.2 Ascendia Pharmaceuticals Business Overview
11.15.3 Ascendia Pharmaceuticals Lipid Nanoparticle CDMO Introduction
11.15.4 Ascendia Pharmaceuticals Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.15.5 Ascendia Pharmaceuticals Recent Development
11.16 Catalent
11.16.1 Catalent Company Details
11.16.2 Catalent Business Overview
11.16.3 Catalent Lipid Nanoparticle CDMO Introduction
11.16.4 Catalent Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.16.5 Catalent Recent Development
11.17 Polymun Scientific
11.17.1 Polymun Scientific Company Details
11.17.2 Polymun Scientific Business Overview
11.17.3 Polymun Scientific Lipid Nanoparticle CDMO Introduction
11.17.4 Polymun Scientific Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.17.5 Polymun Scientific Recent Development
11.18 Patheon
11.18.1 Patheon Company Details
11.18.2 Patheon Business Overview
11.18.3 Patheon Lipid Nanoparticle CDMO Introduction
11.18.4 Patheon Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.18.5 Patheon Recent Development
11.19 Biomay
11.19.1 Biomay Company Details
11.19.2 Biomay Business Overview
11.19.3 Biomay Lipid Nanoparticle CDMO Introduction
11.19.4 Biomay Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.19.5 Biomay Recent Development
11.20 Pace Analytical
11.20.1 Pace Analytical Company Details
11.20.2 Pace Analytical Business Overview
11.20.3 Pace Analytical Lipid Nanoparticle CDMO Introduction
11.20.4 Pace Analytical Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.20.5 Pace Analytical Recent Development
11.21 CordenPharma
11.21.1 CordenPharma Company Details
11.21.2 CordenPharma Business Overview
11.21.3 CordenPharma Lipid Nanoparticle CDMO Introduction
11.21.4 CordenPharma Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.21.5 CordenPharma Recent Development
11.22 Vernal Biosciences
11.22.1 Vernal Biosciences Company Details
11.22.2 Vernal Biosciences Business Overview
11.22.3 Vernal Biosciences Lipid Nanoparticle CDMO Introduction
11.22.4 Vernal Biosciences Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.22.5 Vernal Biosciences Recent Development
11.23 Lonza
11.23.1 Lonza Company Details
11.23.2 Lonza Business Overview
11.23.3 Lonza Lipid Nanoparticle CDMO Introduction
11.23.4 Lonza Revenue in Lipid Nanoparticle CDMO Business (2021–2026)
11.23.5 Lonza Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Lipid Nanoparticle CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Formulation Development
Table 3. Key Players of cGMP Manufacturing
Table 4. Key Players of Others
Table 5. Global Lipid Nanoparticle CDMO Market Size Growth Rate by Service Scope & Project Stage (US$ Million): 2021 vs 2025 vs 2032
Table 6. Key Players of Preclinical Development CDMO
Table 7. Key Players of Clinical Trial CDMO
Table 8. Key Players of Commercial Manufacturing CDMO
Table 9. Global Lipid Nanoparticle CDMO Market Size Growth Rate by Manufacturing Technology (US$ Million): 2021 vs 2025 vs 2032
Table 10. Key Players of Batch Processing CDMO
Table 11. Key Players of Continuous Flow CDMO
Table 12. Key Players of Aseptic Fill-Finish Integrated CDMO
Table 13. Global Lipid Nanoparticle CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 14. Global Lipid Nanoparticle CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Lipid Nanoparticle CDMO Market Size by Region (US$ Million), 2021–2026
Table 16. Global Lipid Nanoparticle CDMO Market Share by Region (2021–2026)
Table 17. Global Lipid Nanoparticle CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 18. Global Lipid Nanoparticle CDMO Market Share by Region (2027–2032)
Table 19. Lipid Nanoparticle CDMO Market Trends
Table 20. Lipid Nanoparticle CDMO Market Drivers
Table 21. Lipid Nanoparticle CDMO Market Challenges
Table 22. Lipid Nanoparticle CDMO Market Restraints
Table 23. Global Lipid Nanoparticle CDMO Revenue by Players (US$ Million), 2021–2026
Table 24. Global Lipid Nanoparticle CDMO Market Share by Players (2021–2026)
Table 25. Global Top Lipid Nanoparticle CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Lipid Nanoparticle CDMO Revenue, 2025
Table 26. Ranking of Global Top Lipid Nanoparticle CDMO Companies by Revenue (US$ Million) in 2025
Table 27. Global 5 Largest Players Market Share by Lipid Nanoparticle CDMO Revenue (CR5 and HHI), 2021–2026
Table 28. Global Key Players of Lipid Nanoparticle CDMO, Headquarters and Area Served
Table 29. Global Key Players of Lipid Nanoparticle CDMO, Products and Applications
Table 30. Global Key Players of Lipid Nanoparticle CDMO, Date of General Availability (GA)
Table 31. Mergers and Acquisitions, Expansion Plans
Table 32. Global Lipid Nanoparticle CDMO Market Size by Type (US$ Million), 2021–2026
Table 33. Global Lipid Nanoparticle CDMO Revenue Market Share by Type (2021–2026)
Table 34. Global Lipid Nanoparticle CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 35. Global Lipid Nanoparticle CDMO Revenue Market Share by Type (2027–2032)
Table 36. Global Lipid Nanoparticle CDMO Market Size by Application (US$ Million), 2021–2026
Table 37. Global Lipid Nanoparticle CDMO Revenue Market Share by Application (2021–2026)
Table 38. Global Lipid Nanoparticle CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 39. Global Lipid Nanoparticle CDMO Revenue Market Share by Application (2027–2032)
Table 40. North America Lipid Nanoparticle CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. North America Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2021–2026
Table 42. North America Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2027–2032
Table 43. Europe Lipid Nanoparticle CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Europe Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. Europe Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Asia-Pacific Lipid Nanoparticle CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 47. Asia-Pacific Lipid Nanoparticle CDMO Market Size by Region (US$ Million), 2021–2026
Table 48. Asia-Pacific Lipid Nanoparticle CDMO Market Size by Region (US$ Million), 2027–2032
Table 49. Latin America Lipid Nanoparticle CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 50. Latin America Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2021–2026
Table 51. Latin America Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2027–2032
Table 52. Middle East & Africa Lipid Nanoparticle CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 53. Middle East & Africa Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2021–2026
Table 54. Middle East & Africa Lipid Nanoparticle CDMO Market Size by Country (US$ Million), 2027–2032
Table 55. GenScript Company Details
Table 56. GenScript Business Overview
Table 57. GenScript Lipid Nanoparticle CDMO Product
Table 58. GenScript Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 59. GenScript Recent Development
Table 60. Creative Biolabs Company Details
Table 61. Creative Biolabs Business Overview
Table 62. Creative Biolabs Lipid Nanoparticle CDMO Product
Table 63. Creative Biolabs Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 64. Creative Biolabs Recent Development
Table 65. Merck Company Details
Table 66. Merck Business Overview
Table 67. Merck Lipid Nanoparticle CDMO Product
Table 68. Merck Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 69. Merck Recent Development
Table 70. Cytiva Company Details
Table 71. Cytiva Business Overview
Table 72. Cytiva Lipid Nanoparticle CDMO Product
Table 73. Cytiva Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 74. Cytiva Recent Development
Table 75. WuXi STA Company Details
Table 76. WuXi STA Business Overview
Table 77. WuXi STA Lipid Nanoparticle CDMO Product
Table 78. WuXi STA Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 79. WuXi STA Recent Development
Table 80. Carcell Company Details
Table 81. Carcell Business Overview
Table 82. Carcell Lipid Nanoparticle CDMO Product
Table 83. Carcell Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 84. Carcell Recent Development
Table 85. Nippon Fine Chemical Company Details
Table 86. Nippon Fine Chemical Business Overview
Table 87. Nippon Fine Chemical Lipid Nanoparticle CDMO Product
Table 88. Nippon Fine Chemical Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 89. Nippon Fine Chemical Recent Development
Table 90. Detai Biotechnology Company Details
Table 91. Detai Biotechnology Business Overview
Table 92. Detai Biotechnology Lipid Nanoparticle CDMO Product
Table 93. Detai Biotechnology Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 94. Detai Biotechnology Recent Development
Table 95. MicroNano Biologics Company Details
Table 96. MicroNano Biologics Business Overview
Table 97. MicroNano Biologics Lipid Nanoparticle CDMO Product
Table 98. MicroNano Biologics Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 99. MicroNano Biologics Recent Development
Table 100. Precigenome Company Details
Table 101. Precigenome Business Overview
Table 102. Precigenome Lipid Nanoparticle CDMO Product
Table 103. Precigenome Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 104. Precigenome Recent Development
Table 105. Evonik Company Details
Table 106. Evonik Business Overview
Table 107. Evonik Lipid Nanoparticle CDMO Product
Table 108. Evonik Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 109. Evonik Recent Development
Table 110. Lipoid Company Details
Table 111. Lipoid Business Overview
Table 112. Lipoid Lipid Nanoparticle CDMO Product
Table 113. Lipoid Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 114. Lipoid Recent Development
Table 115. Helix Biotech Company Details
Table 116. Helix Biotech Business Overview
Table 117. Helix Biotech Lipid Nanoparticle CDMO Product
Table 118. Helix Biotech Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 119. Helix Biotech Recent Development
Table 120. FUJIFILM Holdings Company Details
Table 121. FUJIFILM Holdings Business Overview
Table 122. FUJIFILM Holdings Lipid Nanoparticle CDMO Product
Table 123. FUJIFILM Holdings Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 124. FUJIFILM Holdings Recent Development
Table 125. Ascendia Pharmaceuticals Company Details
Table 126. Ascendia Pharmaceuticals Business Overview
Table 127. Ascendia Pharmaceuticals Lipid Nanoparticle CDMO Product
Table 128. Ascendia Pharmaceuticals Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 129. Ascendia Pharmaceuticals Recent Development
Table 130. Catalent Company Details
Table 131. Catalent Business Overview
Table 132. Catalent Lipid Nanoparticle CDMO Product
Table 133. Catalent Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 134. Catalent Recent Development
Table 135. Polymun Scientific Company Details
Table 136. Polymun Scientific Business Overview
Table 137. Polymun Scientific Lipid Nanoparticle CDMO Product
Table 138. Polymun Scientific Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 139. Polymun Scientific Recent Development
Table 140. Patheon Company Details
Table 141. Patheon Business Overview
Table 142. Patheon Lipid Nanoparticle CDMO Product
Table 143. Patheon Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 144. Patheon Recent Development
Table 145. Biomay Company Details
Table 146. Biomay Business Overview
Table 147. Biomay Lipid Nanoparticle CDMO Product
Table 148. Biomay Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 149. Biomay Recent Development
Table 150. Pace Analytical Company Details
Table 151. Pace Analytical Business Overview
Table 152. Pace Analytical Lipid Nanoparticle CDMO Product
Table 153. Pace Analytical Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 154. Pace Analytical Recent Development
Table 155. CordenPharma Company Details
Table 156. CordenPharma Business Overview
Table 157. CordenPharma Lipid Nanoparticle CDMO Product
Table 158. CordenPharma Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 159. CordenPharma Recent Development
Table 160. Vernal Biosciences Company Details
Table 161. Vernal Biosciences Business Overview
Table 162. Vernal Biosciences Lipid Nanoparticle CDMO Product
Table 163. Vernal Biosciences Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 164. Vernal Biosciences Recent Development
Table 165. Lonza Company Details
Table 166. Lonza Business Overview
Table 167. Lonza Lipid Nanoparticle CDMO Product
Table 168. Lonza Revenue in Lipid Nanoparticle CDMO Business (US$ Million), 2021–2026
Table 169. Lonza Recent Development
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
Table 173. Authors List of This Report
List of Figures
Figure 1. Lipid Nanoparticle CDMO Picture
Figure 2. Global Lipid Nanoparticle CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Lipid Nanoparticle CDMO Market Share by Type: 2025 vs 2032
Figure 4. Formulation Development Features
Figure 5. cGMP Manufacturing Features
Figure 6. Others Features
Figure 7. Global Lipid Nanoparticle CDMO Market Size Comparison by Service Scope & Project Stage (US$ Million), 2021–2032
Figure 8. Preclinical Development CDMO Features
Figure 9. Clinical Trial CDMO Features
Figure 10. Commercial Manufacturing CDMO Features
Figure 11. Global Lipid Nanoparticle CDMO Market Size Comparison by Manufacturing Technology (US$ Million), 2021–2032
Figure 12. Batch Processing CDMO Features
Figure 13. Continuous Flow CDMO Features
Figure 14. Aseptic Fill-Finish Integrated CDMO Features
Figure 15. Global Lipid Nanoparticle CDMO Market Size by Application (US$ Million), 2021–2032
Figure 16. Global Lipid Nanoparticle CDMO Market Share by Application: 2025 vs 2032
Figure 17. Gene Therapy Case Studies
Figure 18. Vaccine Development Case Studies
Figure 19. Cancer Treatment Case Studies
Figure 20. Lipid Nanoparticle CDMO Report Years Considered
Figure 21. Global Lipid Nanoparticle CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 22. Global Lipid Nanoparticle CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Lipid Nanoparticle CDMO Market Share by Region: 2025 vs 2032
Figure 24. Global Lipid Nanoparticle CDMO Market Share by Players in 2025
Figure 25. Global Lipid Nanoparticle CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 26. The Top 10 and 5 Players Market Share by Lipid Nanoparticle CDMO Revenue in 2025
Figure 27. North America Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. North America Lipid Nanoparticle CDMO Market Share by Country (2021–2032)
Figure 29. United States Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Canada Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Europe Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Europe Lipid Nanoparticle CDMO Market Share by Country (2021–2032)
Figure 33. Germany Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. France Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. U.K. Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Italy Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Russia Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Ireland Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Asia-Pacific Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Asia-Pacific Lipid Nanoparticle CDMO Market Share by Region (2021–2032)
Figure 41. China Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Japan Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. South Korea Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Southeast Asia Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. India Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Australia & New Zealand Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Latin America Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Latin America Lipid Nanoparticle CDMO Market Share by Country (2021–2032)
Figure 49. Mexico Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Brazil Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Middle East & Africa Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Middle East & Africa Lipid Nanoparticle CDMO Market Share by Country (2021–2032)
Figure 53. Israel Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Saudi Arabia Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. UAE Lipid Nanoparticle CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. GenScript Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 57. Creative Biolabs Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 58. Merck Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 59. Cytiva Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 60. WuXi STA Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 61. Carcell Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 62. Nippon Fine Chemical Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 63. Detai Biotechnology Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 64. MicroNano Biologics Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 65. Precigenome Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 66. Evonik Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 67. Lipoid Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 68. Helix Biotech Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 69. FUJIFILM Holdings Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 70. Ascendia Pharmaceuticals Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 71. Catalent Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 72. Polymun Scientific Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 73. Patheon Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 74. Biomay Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 75. Pace Analytical Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 76. CordenPharma Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 77. Vernal Biosciences Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 78. Lonza Revenue Growth Rate in Lipid Nanoparticle CDMO Business (2021–2026)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
